- Open Access
Inter-rater reliability and concurrent validity of ROBINS-I: protocol for a cross-sectional study
Systematic Reviews volume 9, Article number: 12 (2020)
The Cochrane Bias Methods Group recently developed the “Risk of Bias (ROB) in Non-randomized Studies of Interventions” (ROBINS-I) tool to assess ROB for non-randomized studies of interventions (NRSI). It is important to establish consistency in its application and interpretation across review teams. In addition, it is important to understand if specialized training and guidance will improve the reliability of the results of the assessments. Therefore, the objective of this cross-sectional study is to establish the inter-rater reliability (IRR), inter-consensus reliability (ICR), and concurrent validity of ROBINS-I. Furthermore, as this is a relatively new tool, it is important to understand the barriers to using this tool (e.g., time to conduct assessments and reach consensus—evaluator burden).
Reviewers from four participating centers will appraise the ROB of a sample of NRSI publications using the ROBINS-I tool in two stages. For IRR and ICR, two pairs of reviewers will assess the ROB for each NRSI publication. In the first stage, reviewers will assess the ROB without any formal guidance. In the second stage, reviewers will be provided customized training and guidance. At each stage, each pair of reviewers will resolve conflicts and arrive at a consensus. To calculate the IRR and ICR, we will use Gwet’s AC1 statistic.
For concurrent validity, reviewers will appraise a sample of NRSI publications using both the New-castle Ottawa Scale (NOS) and ROBINS-I. We will analyze the concordance between the two tools for similar domains and for the overall judgments using Kendall’s tau coefficient.
To measure the evaluator burden, we will assess the time taken to apply the ROBINS-I (without and with guidance), and the NOS. To assess the impact of customized training and guidance on the evaluator burden, we will use the generalized linear models. We will use Microsoft Excel and SAS 9.4 to manage and analyze study data, respectively.
The quality of evidence from systematic reviews that include NRS depends partly on the study-level ROB assessments. The findings of this study will contribute to an improved understanding of the ROBINS-I tool and how best to use it.
Systematic reviews provide the best available evidence to inform healthcare decision-making . The strength, or quality, of the evidence from systematic reviews depends partly on the internal validity of the included studies . Evidence from randomized controlled trials (RCT) is superior to evidence originating from non-randomized studies (NRS) due to potential biases associated with the design and conduct of NRS . Even so, it is important to include NRS in systematic reviews when evidence from RCTs is indirect, imprecise, inconsistent, inapplicable, or unavailable [3, 4]. As such, reviewers must be aware of the potential biases due to the design and conduct of NRS and the best practices to minimize the impact of these biases on the effect estimate .
Many quality assessment tools are available to assess the methodological quality of NRS [6,7,8]. Although unpublished to this day, the Newcastle-Ottawa scale (NOS) is the most widely used quality assessment tool for NRS . NOS is eight items divided into three domains (selection, comparability, and either outcome or exposure assessment for cohort and case-control studies, respectively). Reviewers rate study quality using a star system with a maximum of one star assigned to all eight items (except for one item under comparability domain, which receives a maximum of two stars); total scores can range between 0 and 9 stars . Although the NOS is widely used, it was reported to have poor inter-rater reliability .
Furthermore, in recent years, as our understanding of the potential effects of study design, study conduct, and study reporting has improved, there has been a major shift from using checklists for assessing study quality (or just reporting per se) to assessing ROB [9, 10]. While it may be counterintuitive, study quality, reporting, and risk of bias are not synonymous with each other; well-designed and conducted trials may be poorly reported and not all biases will relate to poor study quality and vice versa.
Over the years, researchers have developed hybrid ROB assessment tools by modifying existing available instruments. In 2014, the Cochrane Bias Methods Group developed “A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI) . This initial version of the tool was finalized and renamed the “Risk of Bias in Non-randomized Studies of Interventions” (ROBINS-I) in 2016 . The ROBINS-I guides judgment about the ROB in an estimate of (a beneficial or harmful) effect of an intervention investigated in a NRS of interventions (NRSI) from the perspective of a hypothetical target RCT that the NRS best emulates (even if the RCT would be unethical or unfeasible) [2, 12]. The ROBINS-I tool is composed of seven domains to assess bias due to confounding, selection of participants, classification of interventions, departures from intended interventions, missing data, measurement of outcomes, and selection of reported results . Each of the seven domains contains multiple signaling questions with five response options (yes, probably yes, no, probably no, or no information) to guide domain level ROB adjudications . The ROB adjudications are categorized as follows: low risk, moderate risk, serious risk, critical risk, or no information. Although the use of ROBINS-I tool is currently very limited, it is expected to steadily increase with time.
Since ROBINS-I is a relatively new instrument, it is important to assess its psychometric properties. It is highly essential to establish ample evidence on its reliability and validity in order to assess and improve the consistency in its application and in how it is interpreted across various systematic reviews that include evidence from NRSI. Inter-rater reliability (IRR) refers to the reproducibility or consistency of decisions between two reviewers and is a necessary component of validity [13, 14]. Inter-consensus reliability (ICR) refers to the comparison of consensus assessments across pairs of reviewers in the participating centers. Concurrent validity refers to the extent to which the results of the instrument or tool can be trusted . Furthermore, it is important to understand the barriers to using this tool (e.g., time to conduct assessments and reach consensus—evaluator burden).
An international team of experienced researchers from four participating centers will collaboratively undertake this study. The major objectives are to
Measure the IRR and ICR between reviewers when assessing ROB of NRSI using ROBINS-I (without and with customized training and guidance);
Measure the concurrent validity of ROBINS-I;
Measure the evaluator burden (time taken to apply ROBINS-I, time taken to arrive at a consensus, time taken to apply NOS);
In order to address the above objectives, we will conduct a cross-sectional analytical study on a sample of NRSI publications following this protocol. This protocol will be registered with the Open Science Framework (https://osf.io/). The final study manuscript will be reported according to the STROBE-cross-sectional checklist [15,16,17]. We plan to report any protocol amendments in the final study manuscript.
Inter-rater reliability and inter-consensus reliability
Our first objective is to evaluate the inter-rater reliability (IRR) of ROBINS-I at first stage, without customized training and guidance document from the principal investigator, and then at the second stage, with customized training and guidance. At both stages, assessors will have access to the publicly available detailed-guidance developed by the ROBINS-I group. For the second stage, a customized guidance document will be developed using Microsoft word (Word v1.5, Microsoft Corp., Redmond, WA, USA), by a senior member of the team holding Ph.D. degree (MJ). Following review and feedback by another experienced senior member of the team (MA), we will finalize the document. The guidance document will contain simplified decision rules, additional guidance for advanced concepts, as well as clarifications on answering signaling questions that will guide reviewers in making adjudications for each domain in ROBINS-I tool. Once developed, we will send the guidance document to all the reviewers, for help with adjudications in the second stage of the project. Additionally, one training session (via Skype), will be organized by a trainer (MJ) who is a senior member of the team and the developer of the customized guidance document. During the training session, the trainer will review the guidance document with all the reviewers and provide clarifications. We will use the following methods to assess IRR and inter-consensus reliability (ICR).
We will involve two pairs of reviewers (LC, NA, RCR, MP, and JX) with varying levels of experience and academic degrees attained, from multiple research teams to assess IRR and ICR. The participating teams are as follows: (coordinating center) The Knowledge Synthesis platform, George and Fay Yee Center for Healthcare Innovation, University of Manitoba (Canada) (MJ, AMAS, LC, NA, RR); Knowledge Synthesis Team, Knowledge Translation Program, Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto (Canada) (ACT and RCR); Institute of Health Economics (IHE) (Canada) (MP); and Nottingham Ningbo GRADE Centre (China) (JX).
Sample size calculation
We have calculated the sample size (number of NRSI publications) required for IRR assessments (n = 44) by taking into account a 5% type I error, 80% statistical power, and an assumed error margin of 30% [18,19,20]. As suggested by Gwet [18, 19], we assumed the chance-agreement probability (Pe) as 0 (best-case scenario) and estimated the required sample size for IRR using the formulas and calculations available at http://agreestat.com/blog_irr/sample_size_determination.html. We obtained the observed-agreement probability (Pa) between reviewers required for sample size calculation from an initial pilot testing of 10 NRSI publications.
We propose to use a sample of NRSI publications (n = 44, based on the sample size calculations) identified through a PubMed (NLM) search of cardiology clinical trials published in English. We will then identify one pre-specified outcome (the primary outcome of each study), for ROB appraisals for each of the included NRSI. With the help of a content expert (SM), we will identify a list of confounders and important co-interventions for the specific association of interest reported in each of the included NRSI publications.
After the initial pilot testing on 10 studies, we will proceed with ROB assessments for IRR. We will advise the reviewers to review the available general guidelines for ROBINS-I provided by the developers of the ROBINS-I tool available at https://methods.cochrane.org/news/robins-i-tool. We will also advise all reviewers in the participating centers to read the full report of each included NRSI prior to making assessments. Reviewers will have the list of confounders and important co-interventions available during their assessments. At first, two reviewers will independently, and in duplicate, assess the ROB for the included NRSI using the ROBINS-I tool, without using any formal training or customized guidance. For each included NRS, the two reviewers will assess the seven domains of the ROBINS-I tool as low ROB, moderate ROB, serious ROB, critical ROB, or no information  (Table 1). In the end, the two reviewers will resolve conflicts and arrive at a consensus.
As a next step, each pair of reviewers will re-assess the same set of NRSI following formal training and using a customized guidance sheet following the initial “without guidance” ROB assessments. At the end of the assessments, again the reviewers will meet to resolve conflicts and arrive at a consensus. All studies are assessed first without guidance, before any with-guidance assessments, to prevent the possibility of with-guidance assessment influencing without-guidance assessment. The principal investigator (MJ) at the coordinating center will coordinate this process among reviewers in the different participating centers.
Upon completion, the collaborating center will collect, organize, and transfer the ROB assessment data from various reviewers to an Excel workbook, prior to proceeding with the data analysis. We will then assess and report the IRR and ICR for ROB assessments “without guidance,” and “with guidance,” separately.
An experienced biostatistician (RR) from the collaborating center will conduct all the analyses in collaboration with the other members of the research team. We will transfer all collected data from the Microsoft Excel workbook (Excel v14, Microsoft Corp., Redmond, WA, USA) to SAS (9.4), (SAS Institute Inc., Cary, NC, USA) for analysis. The kappa (κ) statistic is typically used to assess IRR as it corrects for the “chance” agreement between the two reviewers and allows for different types of disagreements to have differing weights . The chance-agreement probability evaluated by the κ statistic assumes that all observed ratings may yield agreements by chance, thus leading to unpredictable results in the presence of high agreement between reviewers . The AC1 statistic developed by Gwet  calculates the true overall chance agreement in the presence of high agreement reviewers, thus yielding values closer to “true” IRR . We will also analyze inter-consensus reliability (ICR) using Gwet’s AC1 statistic .
The agreements among reviewers (IRR and ICR) will be categorized as follows : poor (0), slight (0.1–0.2), fair (0.21–0.4), moderate (0.41–0.6), substantial (0.61–0.8) or near-perfect (0.81–0.99). We will tabulate the AC1 values and the 95% confidence intervals (CIs) separately (without or with guidance), as shown in Table 2. Additionally, we will assess the correlations between adjudications made during both the stages (“with guidance” and “without guidance”) for each of the reviewers to ensure that the effect of training and guidance is not biased.
The second objective of this study is to evaluate the concurrent validity of the ROBINS-I compared to NOS. Concurrent validity refers to how well a newly developed tool is correlated to similar domains of a widely used tool at the same point in time . In other words, concurrent validity evaluates the extent to which there is concordance in judgment for similar domains in both the tools that are being compared . Currently, there is no “gold standard” tool to asses ROB in NRSI. Hence, to assess the concurrent validity of ROBINS-I, we propose to use NOS, as it the most commonly used quality assessment tool for NRSI that had been previously recommended by Cochrane .
In this cross-sectional study, we will explore the concordance between assessments made on similar domains in ROBINS-I and NOS, and the overall assessments for each included NRS.
As mentioned previously, we will use a sample of NRS (n = 44) for assessments of concurrent validity. We have compared and matched both NOS and ROBINS-I (as shown in Tables 3 and 4) to identify the items that completely overlap, partially overlap, or unique to each tool. Since the theoretical construct differs between NOS (methodological quality) and ROBINS-I (ROB), we did not expect a complete match between all domains.
For the assessment of concurrent validity, one reviewer (MJ) with expertise in systematic reviews will assess NOS on a sample of NRSI (n = 44). We will then compare these NOS adjudications with the after-consensus ROBINS-I adjudications (done after customized training and guidance by two pairs of reviewers) for the same set of studies that were used for the ICR assessments.
We will calculate the correlation between the two tools for each of the domains and for the overall assessments. For comparison of overall assessments between the two tools, we will use the following algorithm: 0–2 stars in NOS will be considered similar to “critical ROB” in ROBINS-I, 3–5 stars in NOS will be considered as similar to “serious ROB” in ROBINS-I, 6–8 stars in NOS will be considered as similar to “moderate ROB” in ROBINS-I, and 9 stars in NOS will be considered as similar to “low ROB” in ROBINS-I. In addition, for any discordance observed between domains or overall assessment, we will explore the possible reasons and attempt to provide explanations.
An experienced biostatistician (RR) from the collaborating center will conduct all the analyses in collaboration with the other members of the research team. We will transfer all collected data from the Excel workbook to SAS (9.4), (SAS Institute Inc., Cary, NC, USA) for analysis.
We will use the following algorithm for comparison between similar items (partially or completely overlapping) in the two tools (NOS and ROBINS-I):
For the “selection” domain in NOS: assessments with four stars will be considered equivalent to “low ROB” adjudication in ROBINS-I. Assessments with three stars will be considered equivalent to “moderate ROB” adjudication in ROBINS-I. Assessments with two stars will be considered equivalent to “serious ROB” adjudication in ROBINS-I, and assessments with zero or one star will be considered equivalent to “critical ROB” adjudication in ROBINS-I.
For the “comparability” domain in NOS: assessments with two stars will be considered equivalent to “low ROB” adjudication in ROBINS-I. Assessments with one star will be considered equivalent to “moderate ROB” adjudication in ROBINS-I. Assessments with zero star will be considered equivalent to “serious or critical ROB” adjudication in ROBINS-I.
For the “outcome assessment” domain in NOS: assessments with three stars will be considered equivalent to “low ROB” adjudication in ROBINS-I. Assessments with two stars will be considered equivalent to “moderate ROB” adjudication in ROBINS-I. Assessments with one star will be considered equivalent to “serious ROB” adjudication in ROBINS-I, and assessments with zero star will be considered equivalent to “critical ROB” adjudication in ROBINS-I.
The NOS domains with “no description/no statement” assessments will be considered equivalent to the “no information” adjudication in ROBINS-I.
For measuring concordance or discordance between various domains of NOS and ROBINS-I (i.e., to assess the concurrent validity of ROBINS-I), we will use “Kendall’s tau” a rank correlation coefficient statistic , and its 95% confidence intervals (for ordinal variables) for each domain and for the overall assessments.
The time taken to apply any newly developed instrument is an important factor to consider, as it may contribute to a significant burden on the evaluator/reviewer. It is also important to assess factors that could reduce the application time. In this study, we will compare the time taken to apply ROBINS-I (without and with guidance), time taken by the reviewer pairs to arrive at a consensus (without and with guidance), and the time taken to apply NOS for comparison with ROBINS-I.
Data collection process
Reviewers will record (using a digital clock) the time taken (in minutes) while applying (time to read article plus time to adjudicate) ROBINS-I tool (without and with guidance), time taken for consensus, and the time taken to apply the NOS tool (time to read article plus time to adjudicate) for each included NRS. The reviewers will use the Excel workbook created by the principal investigator to record the start time, end time, and total time to apply ROBINS-I at the completion of the assessment for each NRS and after the consensus process with the second reviewer. The reviewers will split the time to apply ROBINS-I into the time taken to read the full-text of the NRS and the time taken for adjudications. The time to apply ROBINS-I will begin when the reviewer begins reading the full-texts of the NRS and will end when decisions for all domains are completed and an overall ROB assessment for the study is established. The average overall time to apply ROBINS-I for the same set of articles assessed by each reviewer will be calculated. In addition, we will also calculate the time taken to resolve conflicts and arrive at a consensus, and the overall time (time to apply plus time taken to arrive at a consensus) for each pair of reviewers. The time to arrive at a consensus will start when the two reviewers convene to resolve conflicts and will end when they arrive at a consensus.
An experienced biostatistician (RR) from the coordinating center will conduct all the analyses in collaboration with the other members of the research team. We will transfer all collected data from the Excel workbook to SAS (9.4), (SAS Institute Inc., Cary, NC, USA) for analysis.
We will first summarize the average time (mean and SD) taken by the reviewers to assess ROBINS-I without guidance and with guidance separately.
To analyze the impact of customized training and guidance on changes in evaluator burden (ROBINS-I assessment time as well as the time taken by the reviewer pairs to arrive at consensus), we will compare two centers separately (n = 44 respectively). We will use generalized linear models to evaluate changes in the time taken to assess ROBINS-I after customized guidance (compared to without guidance). We will control for the correlation between reviewers using random effects. The distribution of the outcome will be adjusted by using a link function.
To analyze the time taken to apply ROBINS-I compared to NOS we will use a fixed effect, generalized linear model. The model distribution will be chosen by link function.
Systematic reviews that include NRS can provide valuable evidence on rare outcomes, adverse events, long-term outcomes, real-world practice, and in situations where RCTs are unavailable [12, 28]. It is very important to appraise the risk of bias in the included NRS to have a complete understanding of the strengths and weaknesses of the overall evidence, as methodological flaws in the design or conduct of the NRS could lead to biased effect estimates . The newly developed ROBINS-I could be a very useful tool for researchers in assessing the risk of bias in NRS when undertaking systematic reviews of NRS. As such, it is important to evaluate the usability, reliability, and concurrent validity of this tool to help identify potential barriers and facilitators in applying this tool in a real-world setting.
In this cross-sectional study protocol, we describe the methods we will use to assess the inter-rater reliability, inter-consensus reliability, and the concurrent validity of ROBINS-I. Our proposed study, upon completion, will provide empirical evidence on the IRR, concurrent validity, and the evaluator burden of ROBINS-I.
Strengths and challenges
Across the world, researchers, with a range of expertise, conduct systematic reviews that include NRSI. ROBINS-I tool was designed to be used by all systematic reviewers with varied academic backgrounds and experience. A major strength of our study is that we will involve reviewers from multiple research teams with a range of expertise and academic backgrounds (highest degree attained) to apply and test ROBINS-I, in order to simulate the real-world settings. We will also use a sample of NRS that were not evaluated previously by the reviewers, in order to mimic what is typically encountered in a real-world setting. As with any elaborate tool, it is important to evaluate concerns regarding the practical use of ROBINS-I. To the best of our knowledge, there are two studies [29, 30] that have assessed the IRR of ROBINS-I. In Losilla et al. , using a sample of studies on health psychology, the IRR for ROBINS-I was reported to range from slight to an almost perfect agreement for various items and domains using the kappa statistic. Whereas in Minozzi et al. , using Fleiss’ Kappa statistic, the IRR for ROBINS-I for all domains were reported to be only of slight agreement. To the best of our knowledge, there are no studies that have assessed the impact of additional training/guidance on IRR, the impact of additional training/guidance on evaluator burden, the ICR, the impact of additional training/guidance on the ICR, and also the construct validity of ROBINS-I (comparison of ROBINS-I with NOS).
The findings of our cross-sectional study have a potential to elucidate the impact of training and development of customized guidance with decision rules on the IRR, ICR, and the evaluator burden of ROBINS-I. Also, for data analysis, we will use the AC1 statistic developed by Gwet  to calculate true chance agreement in the presence of high agreement between reviewers, thus yielding values closer to “true” IRR for ROBINS-I.
For feasibility, the reviewers will only appraise ROB for a single outcome for each NRSI. This may be a limitation as reviewers in real-world settings may need to appraise multiple outcomes for each of the included NRSI and the evaluator burden might differ slightly from the findings of this study. In addition, we anticipate that the time taken to assess ROB might be longer for NRSI appraised at the beginning compared to those appraised later, due to increasing familiarity and a learning curve. In a real-world setting, the training and customized guidance decision rules developed by the researchers for their own systematic reviews may differ from the one developed by the principal investigator of this study, and this may pose a challenge in the generalization of the findings of this study. For feasibility, we have proposed to use the same reviewers for both stages (without and with guidance), and we anticipate that this may bias the effect of training and guidance. However, we will address this limitation by assessing the correlations between adjudications made during the two stages, for each of the reviewers. A poor correlation between adjudications made during the two stages, for a reviewer would indicate that the training and guidance have been useful.
As with any new tool, it is critical to assess the IRR, ICR, concurrent validity, and evaluator burden of ROBINS-I, in order to improve the consistency of its application and its interpretation across various systematic reviews that include NRS. We hope that the findings of this study will contribute to an improved understanding and better application of the ROBINS-I tool.
Knowledge dissemination strategy
Systematic reviews serve as a source of knowledge and evidence to aid in the decision-making process. Our cross-sectional study addresses issues that may contribute to the quality of the evidence synthesized by the systematic review and thus will be of great interest to all stakeholders such as clinicians, decision-makers, patients, and the general public. It will also be of great interest to researchers to improve their understanding regarding the practical use of the ROBINS-I tool. We plan to disseminate the results of our cross-sectional study by presenting the study results at various conferences, by publishing study results in academic journals and by spreading the message through social media.
Availability of data and materials
A Cochrane Risk of Bias Assessment Tool for Non-Randomized Studies of Interventions
National Library of Medicine
Non-randomized studies of interventions
Randomized controlled trials
Risk of bias
Risk of Bias in Non-randomized Studies of Interventions
Treadwell JR, Singh S, Talati R, McPheeters ML, Reston JT. In: A Framework for "Best Evidence" Approaches in Systematic Reviews. Rockville (MD)2011.
Schunemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Journal of clinical epidemiology. 2018.
Norris S, Atkins D, Bruening W, et al. Selecting observational studies for comparing medical interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD)2008.
O'Neil M, Berkman N, Hartling L, et al. Observational evidence and strength of evidence domains: case examples. Systematic reviews. 2014;3:35.
Hartling L, Milne A, Hamm MP, et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. Journal of clinical epidemiology. 2013;66(9):982–93.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of epidemiology and community health. 1998;52(6):377–84.
Wells GA, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 2008.
Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. International journal of epidemiology. 2007;36(3):666–76.
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
Whiting P, Savovic J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of clinical epidemiology. 2016;69:225–34.
Sterne JAC, Higgins JPT, Reeves BC. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014. Available from http://www.riskofbias.info. Accessed 19th Jul 2018.
Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.
Cook DA, Beckman TJ. Current concepts in validity and reliability for psychometric instruments: theory and application. The American journal of medicine. 2006;119(2):166 e167–16.
Downing SM. Validity: on meaningful interpretation of assessment data. Medical education. 2003;37(9):830–7.
STROBE Statement - Checklist of items that should be included in reports of cross-sectional studies. http://www.equator-network.org/wp-content/uploads/2015/10/STROBE_checklist_v4_cross-sectional.pdf (Accessed June 2019).
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Annals of internal medicine. 2007;147(8):W163–94.
von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bmj. 2007;335(7624):806–8.
Cantor AB. Sample-size calculations for Cohen's kappa. Psychological methods. 1996;1(2):150–3.
Gwet KL. Sample-size determination. Inter-rater reliability discussion corner. http://agreestat.com/blog_irr/sample_size_determination.html. Last accessed on July 23, 2018. 2010.
Banzi R, Cinquini M, Gonzalez-Lorenzo M, Pecoraro V, Capobussi M, Minozzi S. Quality assessment versus risk of bias in systematic reviews: AMSTAR and ROBIS had similar reliability but differed in their construct and applicability. Journal of clinical epidemiology. 2018.
Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70(4):213–20.
Gwet KL. Computing inter-rater reliability and its variance in the presence of high agreement. The British journal of mathematical and statistical psychology. 2008;61(Pt 1):29–48.
Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL. A comparison of Cohen's Kappa and Gwet's AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC medical research methodology. 2013;13:61.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
DeVon HA, Block ME, Moyle-Wright P, et al. A psychometric toolbox for testing validity and reliability. J Nurs Scholarship. 2007;39(2):155–64.
Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Kendall MG. A new measure of rank correlation. Biometrika. 1938;30(1-2):81–93.
Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American journal of epidemiology. 2016;183(8):758–64.
Losilla JM, Oliveras I, Marin-Garcia JA, Vives J. Three risk of bias tools lead to opposite conclusions in observational research synthesis. Journal of clinical epidemiology. 2018;101:61–72.
Minozzi S, Cinquini M, Gianola S, Castellini G, Gerardi C, Banzi R. Risk of bias in nonrandomized studies of interventions showed low inter-rater reliability and challenges in its application. Journal of clinical epidemiology. 2019;112:28–35.
There is no dedicated funding for this study. ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jeyaraman, M.M., Rabbani, R., Al-Yousif, N. et al. Inter-rater reliability and concurrent validity of ROBINS-I: protocol for a cross-sectional study. Syst Rev 9, 12 (2020). https://doi.org/10.1186/s13643-020-1271-6
- Inter-rater reliability
- Inter-consensus reliability
- Concurrent validity
- Cross-sectional study
- Non-randomized studies